Table 3.

Summary of the answers given by the different groups participating in the survey.

Variable	n
Should the OVHIPEC-1 scheme be used?
NO	1
YES	19
I have doubts	13
Has the publication of OVHIPEC-1 changed your clinical practice?
NO	28
YES	5
What has changed the OVHIPEC-1? (n = 5 groups)
The duration of treatment has been increased	2
The type of drug	1
HIPEC treatment has been included in Interval Cytoreductive Surgery	2
Would a change from your current protocol to OVHIPEC-1 be necessary? (n = 28 groups)
NO	11
YES	17
Do you think more RCT are necessary?
NO	6
YES	27
Do you think HIPEC will be a standard treatment in ovarian cancer?
NO	10
YES	23